Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human Study of RLY-8161 for Treatment of Advanced NRAS-Mutant Melanoma and Other Solid Tumors

NCT07584226 is registered in ClinicalTrials.gov with Relay Therapeutics, Inc. as lead sponsor.

NCT NCT07584226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07584226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human Study of RLY-8161 for Treatment of Advanced NRAS-Mutant Melanoma and Other Solid Tumors
Lead sponsor
Relay Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 9, 2026
Completion date
December 31, 2029
Enrollment
35 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced nras-mutant melanoma, advanced nras-mutant solid tumors, nras g12d, nras g12v, nras g13d, nras g13r, nras mutation, nras q61h, nras q61k, nras q61l, nras q61r